Antioxidant Defenses Confer Resistance to High Dose Melphalan in Multiple Myeloma Cells
Résumé
Multiple myeloma (MM) is the second most common hematological cancer after lymphoma. It is characterized by the accumulation of clonal malignant plasma cells within the bone marrow. The development of drug resistance remains a major problem for effective treatment of MM. Understand the mechanisms underlying drug resistance in MM is a focal point to improve MM treatment.
Domaines
CancerOrigine | Fichiers éditeurs autorisés sur une archive ouverte |
---|